WO2001034180A3 - Interferon gamma pour le traitement de l'asthme - Google Patents

Interferon gamma pour le traitement de l'asthme Download PDF

Info

Publication number
WO2001034180A3
WO2001034180A3 PCT/EP2000/010941 EP0010941W WO0134180A3 WO 2001034180 A3 WO2001034180 A3 WO 2001034180A3 EP 0010941 W EP0010941 W EP 0010941W WO 0134180 A3 WO0134180 A3 WO 0134180A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
ifn
interferon gamma
therapy
treatment
Prior art date
Application number
PCT/EP2000/010941
Other languages
English (en)
Other versions
WO2001034180A2 (fr
Inventor
Lutz-Henning Block
Rolf Ziesche
Original Assignee
Block Lutz Henning
Rolf Ziesche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Block Lutz Henning, Rolf Ziesche filed Critical Block Lutz Henning
Priority to EP00976004A priority Critical patent/EP1227831A2/fr
Priority to AU13923/01A priority patent/AU1392301A/en
Priority to CA002387089A priority patent/CA2387089A1/fr
Priority to JP2001536177A priority patent/JP2003513933A/ja
Publication of WO2001034180A2 publication Critical patent/WO2001034180A2/fr
Publication of WO2001034180A3 publication Critical patent/WO2001034180A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'application clinique réussie et inédite de l'interféron gamma (IFN-η) dans la thérapie de l'asthme bronchique humain. Les données cliniques montrent sans ambiguïté que l'application continue d'IFN-η à doses relativement faibles permet de traiter à long terme l'asthme bronchique grave avec succès, spécialement l'asthme résistant aux glucocorticoïdes. L'invention concerne également une thérapie combinant IFN-η et glucocorticoïdes, qui, administrés seuls, ne sont pas ou pas assez efficaces dans la thérapie de l'asthme.
PCT/EP2000/010941 1999-11-10 2000-11-06 Interferon gamma pour le traitement de l'asthme WO2001034180A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00976004A EP1227831A2 (fr) 1999-11-10 2000-11-06 Interferon gamma pour le traitement de l'asthme
AU13923/01A AU1392301A (en) 1999-11-10 2000-11-06 Interferon gamma for the treatment of asthma
CA002387089A CA2387089A1 (fr) 1999-11-10 2000-11-06 Interferon gamma pour le traitement de l'asthme
JP2001536177A JP2003513933A (ja) 1999-11-10 2000-11-06 喘息治療用インターフェロンガンマ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99122357 1999-11-10
EP99122357.9 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001034180A2 WO2001034180A2 (fr) 2001-05-17
WO2001034180A3 true WO2001034180A3 (fr) 2001-11-08

Family

ID=8239362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010941 WO2001034180A2 (fr) 1999-11-10 2000-11-06 Interferon gamma pour le traitement de l'asthme

Country Status (5)

Country Link
EP (1) EP1227831A2 (fr)
JP (1) JP2003513933A (fr)
AU (1) AU1392301A (fr)
CA (1) CA2387089A1 (fr)
WO (1) WO2001034180A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US6911198B2 (en) 2001-09-17 2005-06-28 Yeda Research And Development Co. Ltd. Method and pharmaceutical composition for treating inflammation
WO2003051388A2 (fr) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Nouvelle composition pharmaceutique d'interferon gamma ou de pirfenidone associe a des agents moleculaires diagnostiques permettant un traitement ameliore des affections pulmonaires interstitielles
EP1430902A1 (fr) * 2002-12-20 2004-06-23 Mondobiotech Laboratories Anstalt Composition pharmaceutique comprenant l'interferon gamma avec diagnostic moléculaire pour un meilleur traitment de l'asthme
US20070031377A1 (en) * 2003-03-28 2007-02-08 Stany Depraetere Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity
EP1516627A1 (fr) * 2003-09-17 2005-03-23 CONARIS research institute AG Interferon-gamma pour le traitement de maladies associées au gène NOD2
US11135223B2 (en) 2016-01-22 2021-10-05 Yale University Compositions and methods for inhibiting Dkk-1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177910A2 (fr) * 1984-10-05 1986-04-16 BIOFERON Biochemische Substanzen GmbH & Co i.K. Application de préparations contenant de l'interféron-gamma (IFN-gamma) pour le traitement systématique de différentes maladies humaines à dose réduite
WO1991007984A1 (fr) * 1989-12-01 1991-06-13 Children's Medical Center Corporation Traitement de troubles atopiques a l'aide d'interferon gamma
EP0795332A2 (fr) * 1996-03-14 1997-09-17 Lutz Henning Prof. Dr. Block Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311616B1 (fr) * 1986-06-17 1991-09-25 Biogen, Inc. Combinaisons d'interferons gamma et d'agents anti-inflammatoires ou anti-pyretiques pour le traitement de maladies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177910A2 (fr) * 1984-10-05 1986-04-16 BIOFERON Biochemische Substanzen GmbH & Co i.K. Application de préparations contenant de l'interféron-gamma (IFN-gamma) pour le traitement systématique de différentes maladies humaines à dose réduite
WO1991007984A1 (fr) * 1989-12-01 1991-06-13 Children's Medical Center Corporation Traitement de troubles atopiques a l'aide d'interferon gamma
EP0795332A2 (fr) * 1996-03-14 1997-09-17 Lutz Henning Prof. Dr. Block Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AIGNER K ET AL: "[Austrian Society for Lung Diseases and Tuberculosis: Consensus on diagnosis and therapy of bronchial asthma in adults. Revised draft 1999]. Osterreichische Gesellschaft fur Lungenerkrankungen und Tuberkulose: Konsensus zur Diagnose und Therapie von Asthma bronchiale bei Erwachsenen. Revidierte Fass", WIENER KLINISCHE WOCHENSCHRIFT, (1999 DEC 23) 111 (24) 1044-7. REF: 0, XP001002671 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, YASUDA MASAKO ET AL: "Effect of dexamethasone on intercellular adhesion molecular-1 expression on cultured bronchial epithelial cells stimulated by inflammatory cytokines.", XP002169884, Database accession no. PREV199598318633 *
JAPANESE JOURNAL OF ALLERGOLOGY, vol. 44, no. 2, 1995, pages 100 - 103, ISSN: 0021-4884 *
See also references of EP1227831A2 *

Also Published As

Publication number Publication date
EP1227831A2 (fr) 2002-08-07
AU1392301A (en) 2001-06-06
CA2387089A1 (fr) 2001-05-17
JP2003513933A (ja) 2003-04-15
WO2001034180A2 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
WO1999046279A3 (fr) INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
WO2001012122A3 (fr) Procede et systeme de traitement de l'arret cardiaque par hypothermie
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2002056912A3 (fr) Methode de traitement du cancer
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
WO2003082212A3 (fr) Methode de traitement du cancer chez les humains
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2004046309A3 (fr) Methodes d'inhibition d'une replication virale in vivo
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
CA2268305A1 (fr) Utilisation d'un inhibiteur de h+, k+-atpase dans le traitement de polypes du nez
WO2001034180A3 (fr) Interferon gamma pour le traitement de l'asthme
EP1304108A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
AU3247201A (en) Gene therapy to promote angiogenesis and/or the treatment of heart failure
EP0795332A3 (fr) Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
WO1999056697A3 (fr) Composition pharmaceutique
WO2000059940A3 (fr) Gene et proteine lies au facteur de croissance d'origine plaquettaire
MXPA02004069A (es) Uso de oxido nitrico para el tratamiento de construccion de vias aereas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2387089

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10129829

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000976004

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536177

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 13923/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000976004

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000976004

Country of ref document: EP